210 related articles for article (PubMed ID: 35297512)
1. Suppression of IL-12/IL-23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon-γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon-driven diseases.
Vincken NLA; Welsing PMJ; Silva-Cardoso SC; Bekker CPJ; Lopes AP; Olde Nordkamp M; Leijten EFA; Radstake TRDJ; Angiolilli C
Exp Dermatol; 2022 Jun; 31(6):962-969. PubMed ID: 35297512
[TBL] [Abstract][Full Text] [Related]
2. The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development.
Stalder R; Zhang B; Jean Wrobel L; Boehncke WH; Brembilla NC
Exp Dermatol; 2020 Jan; 29(1):71-78. PubMed ID: 31721311
[TBL] [Abstract][Full Text] [Related]
3. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
Morelli M; Scarponi C; Mercurio L; Facchiano F; Pallotta S; Madonna S; Girolomoni G; Albanesi C
J Immunol Res; 2018; 2018():7897263. PubMed ID: 30581877
[TBL] [Abstract][Full Text] [Related]
4. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
Artamonova OG; Karamova AE; Nikonorov AA; Verbenko DA; Vasileva EL; Kubanov AA
Bull Exp Biol Med; 2021 May; 171(2):208-211. PubMed ID: 34173094
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Krueger J; Clark JD; Suárez-Fariñas M; Fuentes-Duculan J; Cueto I; Wang CQ; Tan H; Wolk R; Rottinghaus ST; Whitley MZ; Valdez H; von Schack D; O'Neil SP; Reddy PS; Tatulych S;
J Allergy Clin Immunol; 2016 Apr; 137(4):1079-1090. PubMed ID: 27059729
[TBL] [Abstract][Full Text] [Related]
7. Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib.
Wang A; Rahman NT; McGeary MK; Murphy M; McHenry A; Peterson D; Bosenberg M; Flavell RA; King B; Damsky W
J Allergy Clin Immunol; 2021 May; 147(5):1795-1809. PubMed ID: 33317858
[TBL] [Abstract][Full Text] [Related]
8.
Larid G; Delwail A; Dalle T; Vasseur P; Silvain C; Jégou JF; Morel F; Lecron JC; Gervais E
Front Immunol; 2022; 13():993363. PubMed ID: 36426370
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Ighani A; Georgakopoulos JR; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):400-410. PubMed ID: 32348084
[TBL] [Abstract][Full Text] [Related]
10. Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Hashimoto T; Sakai K; Sanders KM; Yosipovitch G; Akiyama T
Acta Derm Venereol; 2019 Mar; 99(3):298-303. PubMed ID: 30460374
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
Merola JF; Papp KA; Nash P; Gratacós J; Boehncke WH; Thaçi D; Graham D; Hsu MA; Wang C; Wu J; Young P
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2809-2820. PubMed ID: 32271970
[TBL] [Abstract][Full Text] [Related]
13. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib.
Kristensen LE; Strober B; Poddubnyy D; Leung YY; Jo H; Kwok K; Vranic I; Fleishaker DL; Fallon L; Yndestad A; Gladman DD
Ther Adv Musculoskelet Dis; 2023; 15():1759720X221149965. PubMed ID: 36777695
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A; Mahmood F; Wittmann M; Helliwell P
Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
[TBL] [Abstract][Full Text] [Related]
15. Cytokine profile characterization of naïve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum.
Ruscitti P; Esposito M; Di Cola I; Pellegrini C; De Berardinis A; Mastrangelo M; Gianneramo C; Barile A; Fargnoli MC; Cipriani P
Front Immunol; 2023; 14():1229516. PubMed ID: 37520537
[TBL] [Abstract][Full Text] [Related]
16. Impaired IFN-γ-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients.
Cordes F; Lenker E; Weinhage T; Spille LJ; Bettenworth D; Varga G; Schmidt HH; Foell D
Inflamm Bowel Dis; 2021 May; 27(6):887-901. PubMed ID: 33165509
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Aung WW; Wang C; Xibei J; Horii M; Mizumaki K; Kano M; Okamura A; Kobayashi T; Matsushita T
J Dermatol Sci; 2021 Mar; 101(3):174-184. PubMed ID: 33451905
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib in psoriatic arthritis.
Wang TS; Tsai TF
Immunotherapy; 2017 Nov; 9(14):1153-1163. PubMed ID: 28967798
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
Gao W; McGarry T; Orr C; McCormick J; Veale DJ; Fearon U
Ann Rheum Dis; 2016 Jan; 75(1):311-5. PubMed ID: 26353790
[TBL] [Abstract][Full Text] [Related]
20. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells.
Strengell M; Lehtonen A; Matikainen S; Julkunen I
J Leukoc Biol; 2006 Jun; 79(6):1279-85. PubMed ID: 16551679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
